General drug use-results survey of Hiyasta tablets (PTCL)

General drug use-results survey of Hiyasta tablets for Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) All-Case Survey

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT2031210606

Enrollment

170

Registered

2022-02-10

Start date

2022-02-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients with relapsed or refractory PTCL to whom Hiyasta tablets is administered. Patients in whom recurrent or refractory peripheral T-cell lymphoma (PTCL) was histologically diagnosed.

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
To assess the occurrence of " myelosuppression", " interstitial lung disease", "infectious disease", and "arrhythmia (including QT interval prolongation)" under actual use conditions in patients with relapsed or refractory PTCL treated with tucidinostat.	—

Contacts

Public ContactPost Marketing Surveillance Dept. Post Marketing Surveillance

Meiji Seika Pharma CO., Ltd.

hiyasta_pms@meiji.com+81-3-3273-3395

Outcome results